Chlorozotocin treatment of advanced gastrointestinal cancer

A. Veronesi, M. D. Magri, U. Tirelli, E. Galligioni, F. Figoli, V. Zagonel, S. Tumolo, E. Grigoletto

Research output: Contribution to journalArticle

Abstract

From April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m2 daily for 5 consecutive days (30 mg/m2 in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3% objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosupression. Median survival was 3 months. At the dosage and schedule used, chorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.

Original languageEnglish
Pages (from-to)365-366
Number of pages2
JournalMedical and Pediatric Oncology
Volume11
Issue number5
Publication statusPublished - 1983

Fingerprint

chlorozotocin
Gastrointestinal Neoplasms
Appointments and Schedules
Therapeutics
Drug Therapy
Survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Veronesi, A., Magri, M. D., Tirelli, U., Galligioni, E., Figoli, F., Zagonel, V., ... Grigoletto, E. (1983). Chlorozotocin treatment of advanced gastrointestinal cancer. Medical and Pediatric Oncology, 11(5), 365-366.

Chlorozotocin treatment of advanced gastrointestinal cancer. / Veronesi, A.; Magri, M. D.; Tirelli, U.; Galligioni, E.; Figoli, F.; Zagonel, V.; Tumolo, S.; Grigoletto, E.

In: Medical and Pediatric Oncology, Vol. 11, No. 5, 1983, p. 365-366.

Research output: Contribution to journalArticle

Veronesi, A, Magri, MD, Tirelli, U, Galligioni, E, Figoli, F, Zagonel, V, Tumolo, S & Grigoletto, E 1983, 'Chlorozotocin treatment of advanced gastrointestinal cancer', Medical and Pediatric Oncology, vol. 11, no. 5, pp. 365-366.
Veronesi A, Magri MD, Tirelli U, Galligioni E, Figoli F, Zagonel V et al. Chlorozotocin treatment of advanced gastrointestinal cancer. Medical and Pediatric Oncology. 1983;11(5):365-366.
Veronesi, A. ; Magri, M. D. ; Tirelli, U. ; Galligioni, E. ; Figoli, F. ; Zagonel, V. ; Tumolo, S. ; Grigoletto, E. / Chlorozotocin treatment of advanced gastrointestinal cancer. In: Medical and Pediatric Oncology. 1983 ; Vol. 11, No. 5. pp. 365-366.
@article{a2939337cf5448eb952f74d0a289200b,
title = "Chlorozotocin treatment of advanced gastrointestinal cancer",
abstract = "From April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m2 daily for 5 consecutive days (30 mg/m2 in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3{\%} objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosupression. Median survival was 3 months. At the dosage and schedule used, chorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.",
author = "A. Veronesi and Magri, {M. D.} and U. Tirelli and E. Galligioni and F. Figoli and V. Zagonel and S. Tumolo and E. Grigoletto",
year = "1983",
language = "English",
volume = "11",
pages = "365--366",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Chlorozotocin treatment of advanced gastrointestinal cancer

AU - Veronesi, A.

AU - Magri, M. D.

AU - Tirelli, U.

AU - Galligioni, E.

AU - Figoli, F.

AU - Zagonel, V.

AU - Tumolo, S.

AU - Grigoletto, E.

PY - 1983

Y1 - 1983

N2 - From April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m2 daily for 5 consecutive days (30 mg/m2 in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3% objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosupression. Median survival was 3 months. At the dosage and schedule used, chorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.

AB - From April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m2 daily for 5 consecutive days (30 mg/m2 in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3% objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosupression. Median survival was 3 months. At the dosage and schedule used, chorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021057489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021057489&partnerID=8YFLogxK

M3 - Article

C2 - 6226856

AN - SCOPUS:0021057489

VL - 11

SP - 365

EP - 366

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -